Fig. 5: The therapeutic effects of DR3 are dependent on expression on ILC2s and IL-13.

a A cohort of Rag^−/− Il2rg^−/− mice were adoptively transferred with ILC2s from either WT, Il5^−/− or Il13^−/− mice, n = 8 mice. Moreover, two additional mice cohorts did not receive any ILC2s. Subsequently, mice were placed on HFD for a period of 14 weeks and were intraperitonially treated with either DR3 agonist or isotype control as shown in the timeline. b Total weights were measured once a week, and c fasting blood glucose levels were measured once every two weeks for a period of 14 weeks. d Glucose tolerance test was performed on the 14th week. e the weight of VAT was determined, and f the number of ILC2s per gram of VAT was quantified after 14 weeks. Error bars are the mean ± SD. Statistical analysis, one-way ANOVA (b–d), two-tailed student’s t-test (e, f); ns: non-significant. Mouse image provided with permission from Servier Medical Art.